Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 19/20 | 0.48 |
| ▸ | MAG | P20916 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215708 | 1.00 | CD22 (0.48) | CD22MAG | |
| SCHEMBL25787323 | 0.94 | CD22 (0.51) | CD22MAG | |
| SCHEMBL12061298 | 0.89 | CD22 (0.44) | CD22MAG | |
| SCHEMBL21334206 | 0.88 | CD22 (0.47) | CD22MAG | |
| SCHEMBL18718069 | 0.88 | CD22 (0.47) | CD22MAG | |
| SCHEMBL18718058 | 0.88 | CD22 (0.47) | CD22MAG | |
| SCHEMBL18718049 | 0.87 | CD22 (0.46) | CD22MAG | |
| SCHEMBL17853991 | 0.87 | CD22 (0.48) | CD22MAG | |
| SCHEMBL17857272 | 0.87 | MAG (0.46) | CD22MAG | |
| SCHEMBL17853988 | 0.86 | CD22 (0.48) | CD22MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2017-03-16 | — | — | US | disclosed |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, B3GAT3, LGALS3BP | CD22 214/4885MAG 105/4885 |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, GALNT1, DPAGT1 | CD22 601/4885MAG 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.